170 related articles for article (PubMed ID: 7489566)
1. Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule.
Morecki S; Levi S; Puyesky Y; Slavin S
Cancer Immunol Immunother; 1995 Oct; 41(4):236-42. PubMed ID: 7489566
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of a B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity.
Ciavarra RP; Vitetta ES; Forman J
J Immunol; 1986 Aug; 137(4):1371-5. PubMed ID: 2426362
[TBL] [Abstract][Full Text] [Related]
3. Tumor-cell vaccination induces tumor dormancy in a murine model of B-cell leukemia/lymphoma (BCL1).
Morecki S; Pugatsch T; Levi S; Moshel Y; Slavin S
Int J Cancer; 1996 Jan; 65(2):204-8. PubMed ID: 8567118
[TBL] [Abstract][Full Text] [Related]
4. Idiotypic vaccination as a treatment for a B cell lymphoma.
George AJ; Folkard SG; Hamblin TJ; Stevenson FK
J Immunol; 1988 Sep; 141(6):2168-74. PubMed ID: 3049800
[TBL] [Abstract][Full Text] [Related]
5. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
George AJ; Tutt AL; Stevenson FK
J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853
[TBL] [Abstract][Full Text] [Related]
6. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
Henderson LA; Ciavarra R; Riblet R; Forman J
J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
[TBL] [Abstract][Full Text] [Related]
7. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
8. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.
Briones J; Timmerman JM; Panicalli DL; Levy R
J Natl Cancer Inst; 2003 Apr; 95(7):548-55. PubMed ID: 12671023
[TBL] [Abstract][Full Text] [Related]
9. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
10. Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma.
Pop LM; Smallshaw JE; Tucker TF; Stevenson FK; Vitetta ES
J Immunother; 2005; 28(6):525-34. PubMed ID: 16224269
[TBL] [Abstract][Full Text] [Related]
11. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
[TBL] [Abstract][Full Text] [Related]
12. Molecules recognized by anti-idiotypic monoclonal antibodies to the B cell lymphoma, BCL1.
Tamura GS; McGrath MS; Weissman IL
J Mol Cell Immunol; 1987; 3(4):243-53. PubMed ID: 3509925
[TBL] [Abstract][Full Text] [Related]
13. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo.
Flamand V; Sornasse T; Thielemans K; Demanet C; Bakkus M; Bazin H; Tielemans F; Leo O; Urbain J; Moser M
Eur J Immunol; 1994 Mar; 24(3):605-10. PubMed ID: 8125131
[TBL] [Abstract][Full Text] [Related]
14. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
15. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
Neeson P; Pan ZK; Paterson Y
Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
[TBL] [Abstract][Full Text] [Related]
16. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies.
Cesco-Gaspere M; Benvenuti F; Burrone OR
Cancer Immunol Immunother; 2005 Apr; 54(4):351-8. PubMed ID: 15692846
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with membrane-associated idiotype provides greater and more prolonged protection of animals from tumor challenge than the soluble form of idiotype.
Ghosh SK; White LM; Ghosh R; Bankert RB
J Immunol; 1990 Jul; 145(1):365-70. PubMed ID: 1972719
[TBL] [Abstract][Full Text] [Related]
18. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
19. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
[TBL] [Abstract][Full Text] [Related]
20. Influence of IgH V-region genes on the growth kinetics of a murine B cell leukemia (BCL1).
Ciavarra R; Forman J
J Immunol; 1981 Jan; 126(1):54-8. PubMed ID: 6778917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
